Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse. - Wikidata - wikimedia - TriplyDB

Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse.

Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse.

http://www.wikidata.org/entity/Q36835063

about

Response of transposable elements to environmental stressors Epigenomics of leukemia: from mechanisms to therapeutic applications Copy number analysis of whole-genome data using BIC-seq2 and its application to detection of cancer susceptibility variants.Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study.Tackling the methylome: recent methodological advances in genome-wide methylation profiling DNA methylation profiles and their relationship with cytogenetic status in adult acute myeloid leukemia.What are the endpoints of therapy for acute leukemias? Old definitions and new challenges.TET1 is a maintenance DNA demethylase that prevents methylation spreading in differentiated cells.Structural characterization and subcellular localization of Drosophila organic solute carrier partner 1.Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia.Mechanisms of resistance to decitabine in the myelodysplastic syndrome.Chromatin remodeling is required for gene reactivation after decitabine-mediated DNA hypomethylation.Dnmt3a is essential for hematopoietic stem cell differentiation.Epigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemia.Trisomy 8 Acute Myeloid Leukemia Analysis Reveals New Insights of DNA Methylome with Identification of HHEX as Potential Diagnostic Marker.The H3K27me3 demethylase UTX is a gender-specific tumor suppressor in T-cell acute lymphoblastic leukemia A seven-gene CpG-island methylation panel predicts breast cancer progression Overexpression of tumor suppressor protein OSCP1/NOR1 induces ER stress and apoptosis during development of Drosophila melanogaster.Dissecting DNA hypermethylation in cancer.Epigenetic synergy between decitabine and platinum derivatives The human cadherin 11 is a pro-apoptotic tumor suppressor modulating cell stemness through Wnt/β-catenin signaling and silenced in common carcinomas.Conserved DNA methylation patterns in healthy blood cells and extensive changes in leukemia measured by a new quantitative technique Digging deep into "dirty" drugs - modulation of the methylation machinery.The epigenome of AML stem and progenitor cells Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma.Minimal role of base excision repair in TET-induced global DNA demethylation in HEK293T cells Clonal evolution and devolution after chemotherapy in adult acute myelogenous leukemia.Pretreatment long interspersed element (LINE)-1 methylation levels, not early hypomethylation under treatment, predict hematological response to azacitidine in elderly patients with acute myeloid leukemia DNA methylation: its role in cancer development and therapy.Significance of the NOR1-FOXA1/HDAC2-Slug regulatory network in epithelial-mesenchymal transition of tumor cells.Genome-wide screen of promoter methylation identifies novel markers in melanoma.Chromatin maps, histone modifications and leukemia.Decitabine impact on the endocytosis regulator RhoA, the folate carriers RFC1 and FOLR1, and the glucose transporter GLUT4 in human tumors.Progesterone receptor isoform-specific promoter methylation: association of PRA promoter methylation with worse outcome in breast cancer patients.Age-related epigenetic drift in the pathogenesis of MDS and AML.A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission.The NOR1/OSCP1 proteins in cancer: from epigenetic silencing to functional characterization of a novel tumor suppressor.The hunt for the epiallele.Role of epigenetic therapy in myelodysplastic syndrome.

P2860

Q26797512-6013B335-11E6-4318-B4B2-43B106BD5D18 Q26823403-1F52AF75-74A2-4B58-A1D5-729528B97B43 Q31105539-9476EEE9-6D6D-4129-B45C-A810B72FF855 Q33396282-96DA39B8-759E-4175-825C-28AC7E6AE5AE Q33600124-AD5A1145-C8E9-497E-841C-5D48A0F02F3B Q33680945-2B63A0FA-0147-4596-AC74-C4F1B1271B44 Q33775647-B8051FF7-0D10-4B50-8DEB-5170F8268031 Q33791229-D9503FEF-13C3-4731-9417-B8635783C36D Q33820378-9846DD1E-895F-4354-87AD-927B2E0FA2D1 Q33876297-1C329A7D-070C-42E9-A475-6B4878579A7A Q33961765-0D9EFC35-4B28-45EA-BBBA-66156B4D4CD0 Q33999539-14E3C5B9-F2B6-421C-BB58-14B574FC420C Q34101643-CE3C734F-1B65-4ABD-8A77-8F354CD2D3BC Q34237926-9A8BE8EF-25C3-4718-A613-F47C30A8C682 Q34643306-D8FC0B99-A812-4420-A004-C7420FA03A14 Q34667913-1A11F530-8C44-4DF2-B899-20E9BE9654AF Q35140239-AA0B3631-C832-4547-84EB-3C4EFE45F840 Q35626799-626B461D-F65A-49BE-8005-01AFC7FB82C8 Q35835232-B29613E7-17FD-4863-A4EA-684DB17DAA4C Q36041771-BAC7D222-8C12-4F10-9DF5-E4B6ED8142B3 Q36053915-8B7A97AC-EB24-4072-97DC-B4B168FBE71D Q36186624-5C76D396-F708-4CFC-B560-63D42069233C Q36484120-36C7A643-32CB-4D54-94FA-0282D406EEF7 Q36523796-27C0258A-999A-4D00-9F7A-134AC6EFB2A4 Q36548067-98543553-0980-413B-AA8F-64F25ABCE343 Q36739006-1704A595-8593-4D0F-8F9D-75B568EDCBDA Q36833419-ACE9540F-714D-412B-8B5A-CA26BF873232 Q36842838-4B5E77D6-EF32-496B-8CDA-499A68E50F96 Q36975817-DD46FF0A-2FF6-47DA-ADD1-5660F9976D93 Q36986433-9412744A-24E1-47A6-8515-DD4BEA7E5F7C Q37086113-23832115-6C24-4DD5-9289-E085651FEF20 Q37287368-0F66B46D-AB23-4184-9C26-BDB1C9203507 Q37423780-9B4A1804-CC3B-4DD4-9138-B947457E3AEB Q37493954-FCFCF4C5-FAFA-438F-8AD6-5D324AB6A67D Q37639114-0BA27710-3596-40FC-A4B4-59ECA39A818A Q37683456-AABE4F5A-BF3F-495B-A867-97E3C13061ED Q37694587-F75AF680-5968-4B1D-BBD1-7622E24E865B Q37726411-AA8FCF82-DF74-45DE-B642-96B5D9139380 Q37788636-E3EBCCB2-EB6B-4363-A3F3-45F3FA554209 Q37810062-BEA61F08-D9D4-4397-B5E1-0B038D82F5CF

P2860

Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse.

http://www.wikidata.org/entity/Q36835063

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse.

@en

type

label

Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse.

@en

prefLabel

Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse.

@en

P1433

Q36835063-AF50791C-CCFD-4EBD-A67B-AD6954F15589

P1476

Q36835063-90C6BEAA-8C61-402C-AE07-E68A0E1EB6A6

P2093

Q36835063-02EC2D51-ADB4-4B83-8784-0D2A10A7FA1F

Q36835063-573FAE6B-E596-4D4F-9E68-8242780EA680

Q36835063-69A20AE1-6E0A-4F82-92A2-5E1876FC42B2

Q36835063-783F2E76-C7E4-4319-89EE-55C130A42A21

Q36835063-9BAA7DF7-A547-4BEA-A3A6-87B3C5D612EC

Q36835063-9CB868E4-1BE1-47AF-9C12-646925343225

Q36835063-E6852FC2-2181-4477-9470-D03C42CC8A39

Q36835063-EBDA1D46-F72D-4975-A933-EE5190C53A6B

Q36835063-F32FE93A-8156-4D6D-822A-10E7D4A64E49

P2860

Q36835063-041CC254-AD6B-4597-8C6C-A7E6741B7574

Q36835063-089A32C6-6A36-4D01-95E4-C602DFD08C26

Q36835063-2A5D7B00-B5C3-4281-9346-9ADAC56C79B8

Q36835063-3FAECC1C-7AA0-4090-BF17-F5F9649F6350

Q36835063-41C10C61-2C8C-4096-B53E-474500A3E74B

Q36835063-490E5F96-3FA5-4814-8DB0-ED3A9F6CEFD5

Q36835063-4F1024E9-9711-479E-8A81-A722A607514B

Q36835063-59E1CDAA-E5C4-43CD-AC47-A835BE7A9CD1

Q36835063-5A39A78F-DCF1-46B5-967A-4DDE6C04E7B9

Q36835063-5A9077B8-D331-466E-B6F1-414F3FDACCC8

P304

Q36835063-4D8FED40-0732-4547-A831-DBBE85E7C580

P31

Q36835063-86EB6C46-9437-4DAA-996C-8475FC233C64

P356

Q36835063-2C4EDDEA-096A-4109-AF50-53DBD948B8E7

P407

Q36835063-3775333E-A4FC-4762-B328-950026938E87

P433

Q36835063-C78A96F1-F275-4F6B-90D9-77602655C5C9

P478

Q36835063-69A3C201-B674-454A-8089-68B79E7E4CA5

P50

Q36835063-637577DE-953B-4B26-B7CC-01DA1C47158F

Q36835063-E27DCAD8-F331-4255-8130-65CB6398346F

P577

Q36835063-ADEF383D-909D-4898-8630-27369CB9DBDF

P5875

Q36835063-BE25F8B3-C09D-4C7C-BFDF-FB8CF45D579A

P698

Q36835063-AD90D686-DFA5-4D58-99AC-5186292A733D

P921

Q36835063-3528FBD0-1104-4CC3-9A5B-E92EB062A974

P932

Q36835063-3A14C4C2-F181-4E6D-B55D-2AD4D4B636A6

P356

BLOOD-2007-11-126227

P1433

P1476

Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse.

@en

P2093

Carlos E Bueso-Ramos

http://www.w3.org/2001/XMLSchema#string

Heike Kroeger

http://www.w3.org/2001/XMLSchema#string

Jaroslav Jelinek

http://www.w3.org/2001/XMLSchema#string

Kimie Kondo

http://www.w3.org/2001/XMLSchema#string

Lanlan Shen

http://www.w3.org/2001/XMLSchema#string

Li Zhang

http://www.w3.org/2001/XMLSchema#string

Marcos R H Estécio

http://www.w3.org/2001/XMLSchema#string

Rong He

http://www.w3.org/2001/XMLSchema#string

Woonbok Chung

http://www.w3.org/2001/XMLSchema#string

P2860

High sensitivity mapping of methylated cytosines

Sensitive and quantitative universal Pyrosequencing methylation analysis of CpG sites

Cadherin-13, a mediator of calcium-dependent cell-cell adhesion, is silenced by methylation in chronic myeloid leukemia and correlates with pretreatment risk profile and cytogenetic response to interferon alfa

Inactivation of p57KIP2 by regional promoter hypermethylation and histone deacetylation in human tumors

The epigenomics of cancer

Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5' CpG island methylation.

Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia.

Genome-wide profiling of DNA methylation reveals a class of normally methylated CpG island promoters.

Hypermethylation and silencing of the putative tumor suppressor Tazarotene-induced gene 1 in human cancers.

Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia.

P304

1366-1373

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2007-11-126227

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

112

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Pierre J Issa

Hagop Kantarjian

P577

2008-06-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51399512

http://www.w3.org/2001/XMLSchema#string

P698

18523155

http://www.w3.org/2001/XMLSchema#string

P921

P932

2515110

http://www.w3.org/2001/XMLSchema#string